Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | VDR | P11473 | 10/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709364 | 0.88 | VDR (0.46) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL14086428 | 0.87 | ESR1 (0.44) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL13203635 | 0.87 | ESR1 (0.39) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL13709362 | 0.87 | VDR (0.35) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL13203650 | 0.86 | ESR1 (0.38) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL13709365 | 0.86 | HDAC3 (0.34) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL13709370 | 0.81 | HDAC6 (0.63) | ESR1ARHDAC3HDAC6VDR | |
| SCHEMBL13203646 | 0.76 | VDR (0.36) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL13203652 | 0.75 | VDR (0.36) | ESR1ESR2ARHDAC3HDAC6 | |
| SCHEMBL13203642 | 0.74 | HDAC6 (0.52) | ESR1ARHDAC3HDAC6VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200552-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | ESR1 217/4885ESR2 177/4885AR 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.